A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy
Est. Enrollment: 110 participants
Study Start Date: Aug 09, 2022
Study Completion Date: May 31, 2025
Age: 18+ years
Gender: All
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.